Clopidogrel antiplatelets drug

Description Results NMA

pretreatment with clopidogrel -+aspirin 75–325 mg) (n=1313)

vs.

placebo (+ aspirin 75–325 mg) (n=1345)

double blind

Parallel groups

Sample size: 1313/1345

Primary endpoint: ardiovascular death, MI, or urgent TVR

FU duration:

non fatal MI 0.82 [0.70; 0.96]

vascular events 0.92 [0.87; 0.97]

non fatla stroke 0.89 [0.70; 1.13]

clopidogrel 75 mg daily (n=22961)

vs.

placebo (n=22891)

double-blind

Parallel groups

Sample size: 22961/22891

Primary endpoint: death, reinfarction, or stroke

FU duration: until discharge or up to 4 wee

clopidogrel (300-mg loading dose, followed by 75 mg once daily) (n=-9)

vs.

placebo (n=-9)

double blind

Sample size: -9/-9

Primary endpoint: death, reMI, occlusion

FU duration: 30 days

Vasc events 0.82 [0.73; 0.90]

fatal and non fatal MI 0.78 [0.68; 0.90]

cardiovascular events 0.82 [0.73; 0.90]

Major bleeds 1.38 [1.13; 1.67]

Vasc deaths 0.93 [0.80; 1.08]

Non vasc deaths 0.92 [0.60; 1.40]

fatala and non fatal stroke 0.87 [0.64; 1.18]

refractory ischemia 0.93 [0.83; 1.04]

fatal bleeding 0.74 [0.34; 1.61]

clopidogrel 300 mg immediately, followed by 75 mg once daily + aspirin for 3 to 12 months (n=6259)

vs.

aspirin (+placebo) (n=6303)

double blind

Parallel groups

Sample size: 6259/6303

Primary endpoint: CV death, MI, stroke

FU duration: NA (median <9 months)

Major bleeds 1.24 [1.05; 1.46]

vascular death, MI, stroke 0.94 [0.83; 1.06]

Severe recurrent ischemia 0.93 [0.64; 1.36]

Hemorrhagic stoke 0.67 [0.19; 2.37]

Vasc events 0.94 [0.84; 1.06]

all cause death 0.96 [0.82; 1.13]

Vasc deaths 0.95 [0.81; 1.13]

fatala and non fatal stroke 0.99 [0.70; 1.39]

fatal and non fatal MI 0.86 [0.72; 1.02]

cardiovascular events 0.94 [0.84; 1.06]

fatal bleeding 1.07 [0.53; 2.16]

Double-dose clopidogrel (n=12520)

vs.

Standard-dose clopidogrel (n=12566)

patients were also assigned in an open-label manner to 300 to 325 mg of aspirin once daily or 75- to 100-mg aspirin once daily

about two thirds eventually underwent PCI (although PCI was planned for everyone who was randomized, about a third of the patients did not undergo the procedure because they were not considered suitable based on angiography findings)

open

Factorial plan

Sample size: 12520/12566

Primary endpoint: CV death/MI/stroke

FU duration: 30 days

non fatal MI 0.82 [0.70; 0.96]

vascular events 0.92 [0.87; 0.97]

non fatla stroke 0.89 [0.70; 1.13]

clopidogrel 75 mg daily (n=22961)

vs.

placebo (n=22891)

double-blind

Parallel groups

Sample size: 22961/22891

Primary endpoint: death, reinfarction, or stroke

FU duration: until discharge or up to 4 wee

clopidogrel (300-mg loading dose, followed by 75 mg once daily) (n=-9)

vs.

placebo (n=-9)

double blind

Sample size: -9/-9

Primary endpoint: death, reMI, occlusion

FU duration: 30 days

haemorragic stroke(or intracerebral hemorrhage) 0.34 [0.12; 0.93]

non fatal TE events,bleedings and vascular death* 1.39 [1.18; 1.64]

thrombo-embolic event (cerebral or systemic) 1.43 [1.18; 1.74]

ischemic stroke 2.17 [1.51; 3.11]

All stroke(ischemic+hemorrhagic/fatal+non fatal) 1.71 [1.25; 2.36]

all death 1.02 [0.82; 1.26]

vascular death 1.14 [0.89; 1.48]

major bleeding 1.10 [0.83; 1.45]

fatal stroke(ischemic+hemorrhagic) 0.94 [0.46; 1.95]

fatal bleeding 0.64 [0.25; 1.66]

clopidogrel (75 mg per day) plus aspirin (75–100 mg per day) (n=3335)

vs.

oral anticoagulation therapy (target international normalised ratio of 2·0–3·0) (n=3371)

open

Parallel groups

Sample size: 3335/3371

Primary endpoint: stroke, non-CNS systemic embolus

FU duration: 1.28 y (median)

fatal stroke(ischemic+hemorrhagic) 0.72 [0.59; 0.88]

thrombo-embolic event (cerebral or systemic) 0.90 [0.83; 0.98]

ischemic stroke 0.69 [0.59; 0.81]

thromboembolic event likes(TE event or ischemic stroke or systemic embolism) 0.89 [0.89; 0.89]

All stroke(ischemic+hemorrhagic/fatal+non fatal) 0.73 [0.63; 0.84]

major bleeding 1.57 [1.29; 1.91]

all death 0.98 [0.90; 1.07]

vascular death 1.00 [0.91; 1.11]

haemorragic stroke(or intracerebral hemorrhage) 1.37 [0.79; 2.37]

fatal bleeding 1.56 [0.96; 2.52]

clopidogrel 75 mg daily + aspirin 75-100 mg daily (n=3772)

vs.

aspirin 75-100 mg daily alone (n=3782)

double blind

Parallel groups

Sample size: 3772/3782

Primary endpoint: stroke, MI, systemic embolus, or vascular death

FU duration: 3.7 y

aspirin 162 mg plus clopidogrel 75 mg daily for 1 year (n=56)

vs.

aspirin 162 mg plus placebo daily (n=57)

double blind

Parallel groups

Sample size: 56/57

Primary endpoint: vein graft intimal area

FU duration: 1 y

IDM fatal 0.62 [0.44; 0.88]

IDM totaux 0.63 [0.47; 0.85]

Mortalité totale 0.81 [0.63; 1.06]

AVC fatal 0.95 [0.69; 1.31]

AVC non fatal 1.38 [0.55; 3.42]

IDM non fatal 0.67 [0.37; 1.21]

Non fatal MI 0.84 [0.70; 1.00]

MI,stroke or CVdeath 0.92 [0.84; 1.00]

Death from any cause 0.98 [0.87; 1.10]

Death from cardiovascular causes 0.92 [0.80; 1.07]

severe bleeding 0.88 [0.70; 1.12]

non fatal stroke 0.94 [0.82; 1.07]

vascular event 0.90 [0.63; 1.29]

Clopidogrel 75 mg (n=3223)

vs.

Aspirine 325 mg (n=3229)

Effectifs correspondant à la strate AOMI

double blind

Parallel groups

Sample size: 3223/3229

Primary endpoint: Critère composite

FU duration: 1.91 y

clopidogrel 75 mg once daily (n=9599)

vs.

aspirin 325 mg once daily (n=9586)

Double blind

Parallel groups

Sample size: 9599/9586

Primary endpoint: ischaemic stroke, myocardial infarction, or vascular death

FU duration: mean 1.91 years

clopidogrel 75 mg once daily for two years (n=498)

vs.

Aspirin 160 mg once daily for two years (n=503)

platelet function was also assessed at randomization with the PFA100 method and platelet aggregometry

open

Parallel groups

Sample size: 498/503

Primary endpoint: all-cause death, nonfatal MI, ischemic stroke, and unstable angina

FU duration:

non fatal stroke 0.81 [0.65; 1.00]

moderate bleeding 1.62 [1.27; 2.08]

nonfatal Ischemic stroke 0.82 [0.66; 1.04]

Death from any cause 0.99 [0.86; 1.14]

Death from cardiovascular causes 1.04 [0.87; 1.24]

severe bleeding 1.25 [0.97; 1.61]

Non fatal MI 0.92 [0.74; 1.15]

fatal bleeding 1.53 [0.83; 2.82]

MI,stroke or CVdeath 0.93 [0.83; 1.04]

clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) (n=7802)

vs.

placebo plus low-dose aspirin (n=7801)

Double blind

Parallel groups

Sample size: 7802/7801

Primary endpoint: myocardial infarction, stroke or death from cardiovasculare causes

FU duration: median 28 months

vascular event 0.90 [0.63; 1.29]

Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years (n=9599)

vs.

Aspirin (325 mg) 1x/d (n=9586)

Double blind

Parallel groups

Sample size: 9599/9586

Primary endpoint: ischaemic stroke, myocardial infarction, vascular death

FU duration: 1.91 y

clopidogrel 75 mg once daily for two years (n=498)

vs.

Aspirin 160 mg once daily for two years (n=503)

platelet function was also assessed at randomization with the PFA100 method and platelet aggregometry

open

Parallel groups

Sample size: 498/503

Primary endpoint: all-cause death, nonfatal MI, ischemic stroke, and unstable angina

FU duration:

all cause death 1.52 [0.76; 3.05]

major bleeding 2.97 [0.31; 28.51]

stroke 2.23 [0.69; 7.21]

MI 1.41 [0.54; 3.70]

definite stent thrombosis 1.24 [0.33; 4.60]

clopidogrel plus aspirin (n=1357)

vs.

aspirin alone (n=1344)

open

Parallel groups

Sample size: 1357/1344

Primary endpoint: CV death, MI

FU duration: 19.2 months

MACE 1.78 [0.67; 4.76]

MACE 1.31 [0.30; 5.83]

MACE 0.84 [0.46; 1.51]

MACE 0.00 [0.00; NaN]

Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD (n=355)

vs.

Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD (n=345)

Sample size: 355/345

Primary endpoint:

FU duration:

Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDypñ ·` (n=345)

vs.

Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD (n=340)

Sample size: 345/340

Primary endpoint:

FU duration:

Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD (n=494)

vs.

Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD (n=522)

Sample size: 494/522

Primary endpoint:

FU duration:

Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD (n=37)

vs.

Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD (n=31)

Sample size: 37/31

Primary endpoint:

FU duration:

all cause death 0.70 [0.27; 1.83]

Cardiovascular death 0.37 [0.10; 1.40]

MI 1.11 [0.59; 2.08]

any bleeding 1.17 [0.93; 1.49]

GUSTO severe/moderate bleeding 0.60 [0.32; 1.13]

Cardiovascular death/MI/stent thrombosis 1.01 [0.58; 1.76]

definite stent thrombosis 0.62 [0.20; 1.90]

High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) (n=1109)

vs.

regular clopidogrel dose (n=1105)

open

Parallel groups

Sample size: 1109/1105

Primary endpoint: Cardiovascular death/MI/stent thrombosis

FU duration: 6 months

IDM fatal 0.62 [0.44; 0.88]

IDM totaux 0.63 [0.47; 0.85]

Mortalité totale 0.81 [0.63; 1.06]

AVC fatal 0.95 [0.69; 1.31]

AVC non fatal 1.38 [0.55; 3.42]

IDM non fatal 0.67 [0.37; 1.21]

Clopidogrel 75 mg (n=3223)

vs.

Aspirine 325 mg (n=3229)

Effectifs correspondant à la strate AOMI

double blind

Parallel groups

Sample size: 3223/3229

Primary endpoint: Critère composite

FU duration: 1.91 y

Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years (n=9599)

vs.

Aspirin (325 mg) 1x/d (n=9586)

Double blind

Parallel groups

Sample size: 9599/9586

Primary endpoint: ischaemic stroke, myocardial infarction, vascular death

FU duration: 1.91 y

vascular event 0.90 [0.63; 1.29]

clopidogrel 75 mg once daily for two years (n=498)

vs.

Aspirin 160 mg once daily for two years (n=503)

platelet function was also assessed at randomization with the PFA100 method and platelet aggregometry

open

Parallel groups

Sample size: 498/503

Primary endpoint: all-cause death, nonfatal MI, ischemic stroke, and unstable angina

FU duration:

all cause death 1.52 [0.76; 3.05]

major bleeding 2.97 [0.31; 28.51]

stroke 2.23 [0.69; 7.21]

MI 1.41 [0.54; 3.70]

definite stent thrombosis 1.24 [0.33; 4.60]

clopidogrel plus aspirin (n=1357)

vs.

aspirin alone (n=1344)

open

Parallel groups

Sample size: 1357/1344

Primary endpoint: CV death, MI

FU duration: 19.2 months

MACE 1.78 [0.67; 4.76]

MACE 1.31 [0.30; 5.83]

MACE 0.84 [0.46; 1.51]

MACE 0.00 [0.00; NaN]

Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD (n=355)

vs.

Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD (n=345)

Sample size: 355/345

Primary endpoint:

FU duration:

Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDypñ ·` (n=345)

vs.

Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD (n=340)

Sample size: 345/340

Primary endpoint:

FU duration:

Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD (n=494)

vs.

Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD (n=522)

Sample size: 494/522

Primary endpoint:

FU duration:

Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD (n=37)

vs.

Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD (n=31)

Sample size: 37/31

Primary endpoint:

FU duration:

all cause death 0.70 [0.27; 1.83]

Cardiovascular death 0.37 [0.10; 1.40]

MI 1.11 [0.59; 2.08]

any bleeding 1.17 [0.93; 1.49]

GUSTO severe/moderate bleeding 0.60 [0.32; 1.13]

Cardiovascular death/MI/stent thrombosis 1.01 [0.58; 1.76]

definite stent thrombosis 0.62 [0.20; 1.90]

High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) (n=1109)

vs.

regular clopidogrel dose (n=1105)

open

Parallel groups

Sample size: 1109/1105

Primary endpoint: Cardiovascular death/MI/stent thrombosis

FU duration: 6 months